Circulatory assist devices and associated infections: new therapies, new complications

Authors

  • María Sánchez-Ledesma Servicio de Medicina Interna, Hospital Clínico Universitario de Salamanca, Salamanca, Spain
  • David González-Calle Servicio de Cardiología, Hospital Clínico Universitario de Salamanca, Salamanca, Spain
  • Ana Elvira Laffond Servicio de Cardiología, Hospital Clínico Universitario de Salamanca, Salamanca, Spain
  • Eduardo Villacorta-Argüelles Servicio de Cardiología, Hospital Clínico Universitario de Salamanca, Salamanca, Spain
  • Javier de-la-Fuente-Aguado Servicio de Medicina Interna, Hospital POVISA, Vigo (Pontevedra), Spain

DOI:

https://doi.org/10.32818/reccmi.a5n1a13

Keywords:

circulatory assist devices, endocarditis, heart failure, antibiotherapy.

Abstract

The use of left ventricular assist devices (LVAD) has significantly increased in the past few years. As a result, new complications, such as infections, have emerged. We present the case of the oldest LVAD carrier in our environment. Her cardiovascular disease has significantly improved, although at the cost of recurrent driveline infections and admissions to hospital. Complications associated with the implant of LVAD, such as infections, is a growing and challenging field. An outpatient and multidisciplinary approach might be the key to improve outcomes.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Hanff TC, Birati EY. Left ventricular assist device as destination therapy: a state of the science and art of long-term mechanical circulatory support. Curr Heart Fail Rep. 2019; 16(5): 168-179. https://doi.org/10.1007/s11897-019-00438-x.

Briasoulis A, Inampudi C, Akintoye E, Adegbala O, Alvarez P, Bhama J. Trends in utilization, mortality, major complications, and cost after left ventricular assist device implantation in the United States (2009 to 2014). Am J Cardiol. 2018; 121(10): 1214-1218. https://doi.org/10.1016/j.amj-card.2018.01.041.

Barrio A, Dobarro D, Alzola E, Raposeiras S, González-Santos JM, Sánchez PL. Durable left ventricular assist device therapy in non transplant centers in Spain: initial experience. Rev Esp Cardiol. 2020: S1885-5857(19)30408-6. https://doi.org/10.1016/j.rec.2019.09.025.

Siméon S, Flécher E, Revest M, Niculescu M, Roussel JC, Michel M, et al. Left ventricular assist device-related infections: a multicentric study. Clin Microbiol Infect. 2017; 23(10): 748-751. https://doi.org/10.1016/j.cmi.2017.03.008.

O'Horo JC, Abu Saleh OM, Stulak JM, Wilhelm MP, Baddour LM, Rizwan Sohail M. Left ventricular assist device infections: a systematic review. ASAIO J. 2018; 64(3): 287-294. https://doi.org/10.1097/MAT.0000000000000684.

Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001; 345(20): 1435-1443. https://doi.org/10.1056/NEJMoa012175.

Adams EE, Wrightson ML. quality of life with an LVAD: a misunderstood concept. Heart Lung. 2018; 47(3): 177-183. https://doi.org/10.1016/j.hrtlng.2018.02.003.

Mensa J, Soriano A, García Sánchez JE, Marco F, Letang E, Llinares P, et al. Guía terapéutica antimicrobiana. Madrid. Antares, 2020.

Jennings DL, Chopra A, Chambers R, Morgan JA. Clinical outcomes associated with chronic antimicrobial suppression therapy in patients with continuous-flow left ventricular assist devices. Artif Organs. 2014; 38(10): 875-879. https://doi.org/10.1111/aor.12254.

Published

2020-04-30

How to Cite

1.
Sánchez-Ledesma M, González-Calle D, Laffond AE, Villacorta-Argüelles E, de-la-Fuente-Aguado J. Circulatory assist devices and associated infections: new therapies, new complications. Rev Esp Casos Clin Med Intern [Internet]. 2020 Apr. 30 [cited 2024 Nov. 23];5(1):36-8. Available from: https://www.reccmi.com/RECCMI/article/view/532

Most read articles by the same author(s)